Adyen Stock Analysis: 28% Upside Case for 2026 – Institutional Research Note
This Adyen stock analysis examines one of Europe’s most debated fintech names following a sharp 20% single-session selloff on February 12, 2026. Moschovakis Capital’s…
Sector
Equities
Meituan Stock Analysis: 55% Decline Exposes Critical Risk for 2026 – Institutional Research Note
This Meituan stock analysis examines one of the most dramatic collapses in Chinese internet equities during 2025. Meituan (03690.HK), the dominant on-demand services platform…
Intuit Stock Analysis: 33% Upside Case for 2026 – Institutional Research Note
This Intuit stock analysis identifies one of the most compelling asymmetric opportunities in application software today. INTU trades at $420 — a 50% drawdown…
Mattel Stock Analysis: 31% Crash Reveals 178% Upside Case for 2035 – Institutional Research Note
Mattel stock analysis has become the most searched equity research topic in the consumer discretionary sector this week, and for good reason. On February…
Moody’s Stock Analysis: 27% Upside Case for 2026 – Institutional Research Note
This Moody’s stock analysis identifies one of the most compelling asymmetric opportunities in financial data and analytics for wealth preservation-focused investors. MCO currently trades…
Intesa Sanpaolo Stock Analysis: 20% Upside Case for 2026 – Institutional Research Note
Executive Summary BOTTOM LINE UP FRONT Metric Value Recommendation BUY at €5.97 Fair Value (Base Case) €7.15 Margin of Safety 19.7% Dividend Yield ~6.0%…
Tencent Stock Analysis: 24% Upside Case for 2026 – Institutional Research Note
Tencent stock analysis is at the forefront of institutional conviction in Chinese technology for 2026. At Moschovakis Capital, our proprietary equity research framework has…
LSEG Stock Analysis: 44% Upside Case for 2026 – Institutional Research Note
This LSEG stock analysis examines London Stock Exchange Group plc (LON: LSEG) following a severe AI-fear-driven selloff that has created what our proprietary Wealth…
SMCI Stock Analysis: 10 Disqualifying Factors Exposed for 2026 – Institutional Research Note
This SMCI stock analysis represents a comprehensive institutional equity research note published by the Moschovakis Capital Wealth Preservation Research Division. Our mandate is capital…
Doximity Stock Analysis: 70% Upside Case for 2026 – Institutional Research Note
This Doximity stock analysis identifies what we consider one of the most compelling risk-adjusted opportunities in healthcare technology today. At $33.50 per share, DOCS…